Metabolic Pathway-Targeted Therapy in ALS

V2, Crosslink

🧫

Metabolic Pathway-Targeted Therapy in ALS

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-als-meta

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Metabolic Pathway-Targeted Therapy in ALS ## Background and Rationale This groundbreaking clinical trial represents a precision medicine approach to ALS therapy through comprehensive metabolic pathway targeting based on individual patient metabolomic profiles. Recent advances in systems biology have revealed profound metabolic dysregulation in ALS, including disrupted glucose metabolism, altered lipid homeostasis, and impaired mitochondrial bioenergetics. Rather than pursuing a one-size-fits-a

METHODOLOGY NOTES

**Phase 1: Patient Recruitment and Baseline Assessment (Months 1-3)** • Recruit 180 ALS patients (90 treatment, 90 placebo) meeting revised El Escorial criteria • Inclusion: Age 18-75, disease duration <2 years, ALSFRS-R score ≥30 • Exclusion: FVC <65%, significant comorbidities, prior riluzole intolerance • Conduct comprehensive baseline assessments: ALSFRS-R, FVC, grip strength, metabolomics panel • Obtain blood samples for targeted metabolomics (amino acids, lipids, glucose metabolism) • Perform MR spectroscopy for brain metabolite quantification **Phase 2: Metabolic Pathway Analysis and Stratification (Month 4)** • Analyze baseline metabolomics data using LC-MS/MS and GC-MS platforms • Identify dysregulated pathways: glutamate metabolism, mitochondrial function, lipid oxidation • Stratify patients based on metabolic phenotypes using unsupervised clustering • Randomize within strata to treatment (metabolic cocktail) vs placebo groups **Phase 3: Treatment Administration (Months 5-1

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.905808Z'}
summary	# Metabolic Pathway-Targeted Therapy in ALS ## Background and Rationale This groundbreaking clinical trial represents a precision medicine approach to ALS therapy through comprehensive metabolic pathw
entities	{'genes': ['HK2/PLIN2/PPARGC1A'], 'diseases': ['ALS']}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Improvement in ALS Functional Rating Scale-Revised (ALSFRS-R) slope over 12 months in patients receiving metabolomics-guided personalized metabolic interventions compared to standard care controls.
methodology_notes	Phase 1: Patient Recruitment and Baseline Assessment (Months 1-3) • Recruit 180 ALS patients (90 treatment, 90 placebo) meeting revised El Escorial criteria • Inclusion: Age 18-75, disease duratio
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.905814', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

523

Outgoing

435

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Metabolic Pathway-Targeted Therapy in ALS

derives from (16)

supports (89)

💬 Discussion